X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with AJANTA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA AJANTA PHARMA NATCO PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 24.7 24.5 100.6% View Chart
P/BV x 18.7 10.1 184.8% View Chart
Dividend Yield % 0.6 0.6 103.2%  

Financials

 NATCO PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
AJANTA PHARMA
Mar-16
NATCO PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs8771,720 51.0%   
Low Rs4241,103 38.4%   
Sales per share (Unadj.) Rs223.4194.6 114.8%  
Earnings per share (Unadj.) Rs31.145.2 68.7%  
Cash flow per share (Unadj.) Rs40.350.3 80.1%  
Dividends per share (Unadj.) Rs5.008.00 62.5%  
Dividend yield (eoy) %0.80.6 135.7%  
Book value per share (Unadj.) Rs219.5132.0 166.2%  
Shares outstanding (eoy) m33.0788.77 37.3%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.97.3 40.1%   
Avg P/E ratio x20.931.2 67.1%  
P/CF ratio (eoy) x16.128.1 57.5%  
Price / Book Value ratio x3.010.7 27.7%  
Dividend payout %16.117.7 91.0%   
Avg Mkt Cap Rs m21,504125,299 17.2%   
No. of employees `000NANA-   
Total wages/salary Rs m1,1282,570 43.9%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m7,38917,275 42.8%  
Other income Rs m167166 100.5%   
Total revenues Rs m7,55617,442 43.3%   
Gross profit Rs m1,7935,807 30.9%  
Depreciation Rs m304451 67.6%   
Interest Rs m36649 748.9%   
Profit before tax Rs m1,2905,474 23.6%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3091,460 21.1%   
Profit after tax Rs m1,0274,014 25.6%  
Gross profit margin %24.333.6 72.2%  
Effective tax rate %23.926.7 89.7%   
Net profit margin %13.923.2 59.8%  
BALANCE SHEET DATA
Current assets Rs m3,6817,639 48.2%   
Current liabilities Rs m3,1232,715 115.0%   
Net working cap to sales %7.628.5 26.5%  
Current ratio x1.22.8 41.9%  
Inventory Days Days8943 207.0%  
Debtors Days Days5979 74.6%  
Net fixed assets Rs m7,6856,914 111.2%   
Share capital Rs m331177 186.9%   
"Free" reserves Rs m6,67011,442 58.3%   
Net worth Rs m7,25911,721 61.9%   
Long term debt Rs m955149 642.2%   
Total assets Rs m11,95714,814 80.7%  
Interest coverage x4.5112.9 4.0%   
Debt to equity ratio x0.10 1,036.9%  
Sales to assets ratio x0.61.2 53.0%   
Return on assets %11.727.4 42.5%  
Return on equity %14.234.2 41.3%  
Return on capital %20.746.5 44.5%  
Exports to sales %39.455.1 71.4%   
Imports to sales %5.76.0 94.9%   
Exports (fob) Rs m2,9089,527 30.5%   
Imports (cif) Rs m4211,038 40.6%   
Fx inflow Rs m3,44510,422 33.1%   
Fx outflow Rs m7031,678 41.9%   
Net fx Rs m2,7438,744 31.4%   
CASH FLOW
From Operations Rs m1,4403,264 44.1%  
From Investments Rs m-1,089-2,093 52.0%  
From Financial Activity Rs m-353-1,186 29.7%  
Net Cashflow Rs m-1-15 10.1%  

Share Holding

Indian Promoters % 52.0 73.8 70.5%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 1.6 505.8%  
FIIs % 16.6 7.6 218.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 17.0 152.9%  
Shareholders   25,395 20,968 121.1%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   J.B.CHEMICALS  SUVEN LIFE  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of PNB Fraud, Rising Troubles at PSBs, and Top Cues in Focus Today(Pre-Open)

Share markets in India closed on a negative note yesterday. At the closing bell yesterday, the BSE Sensex stood lower by 236 points and the NSE Nifty closed down by 74 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Feb 20, 2018 09:15 AM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS